John Koconis
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
John Koconis formerly worked at Leo Pharma, Inc., as President & Chief Executive Officer from 1998 to 2014, Timber Pharmaceuticals LLC, as Chief Executive Officer from 2019 to 2020, Timber Pharmaceuticals, Inc., as Chairman, President & Chief Executive Officer from 2021 to 2024, Abbott Laboratories, as Principal, Genzyme Corp., as Head-Global Dermatology & Respiratory in 2016, LEO Pharma A, as Manager-International Marketing, Genzyme Therapeutics Ltd., as Head-Global Dermatology & Respiratory, and Castle Creek Biosciences, Inc., as Chief Commercial Officer & Executive VP from 2016 to 2019.
Mr. Koconis received his undergraduate degree in 1992 from Loyola University of Chicago and Masters Business Admin degree in 1996 from Quinlan School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TREX WIND DOWN INC
0,01% | 07.09.2023 | 400 ( 0,01% ) | 0 $ | 31.03.2024 |
Ehemalige bekannte Positionen von John Koconis
| Unternehmen | Position | Ende |
|---|---|---|
| TREX WIND-DOWN, INC. | Vorstandsvorsitzender | 22.01.2024 |
Timber Pharmaceuticals LLC
 Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | Vorstandsvorsitzender | 01.04.2020 |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01.01.2019 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.07.2016 |
Leo Pharma, Inc.
 Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Vorstandsvorsitzender | 01.01.2014 |
Ausbildung von John Koconis
| Loyola University of Chicago | Undergraduate Degree |
| Quinlan School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TREX WIND-DOWN, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Leo Pharma, Inc.
Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Retail Trade |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
Timber Pharmaceuticals LLC
Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
